Hugues Morel

1.4k total citations · 1 hit paper
36 papers, 758 citations indexed

About

Hugues Morel is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, Hugues Morel has authored 36 papers receiving a total of 758 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 10 papers in Physiology. Recurrent topics in Hugues Morel's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Hugues Morel is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Hugues Morel collaborates with scholars based in France, United States and Belgium. Hugues Morel's co-authors include S. Marchand‐Adam, Christophe Leroyer, A. Dixmier, Christophe Gut‐Gobert, A. Cavaillès, J.-C. Meurice, Graziella Brinchault-Rabin, P. Diot, François Goupil and Nicolás Roche and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Annals of Oncology.

In The Last Decade

Hugues Morel

30 papers receiving 740 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comorbidities of COPD

2013 360 citations A. Cavaillès, Graziella Brinchault-Rabin et al. European Respiratory Review profile →

Peers

Countries citing papers authored by Hugues Morel

Since Specialization

Citations

This map shows the geographic impact of Hugues Morel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hugues Morel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hugues Morel more than expected).

Fields of papers citing papers by Hugues Morel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hugues Morel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hugues Morel. The network helps show where Hugues Morel may publish in the future.

Co-authorship network of co-authors of Hugues Morel

This figure shows the co-authorship network connecting the top 25 collaborators of Hugues Morel. A scholar is included among the top collaborators of Hugues Morel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hugues Morel. Hugues Morel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes of cannabis smoking in patients with lung cancer: findings from KBP-CPHG-2020 2025 ·Respiratory Medicine and Research ·S. Couraud, Olivier Molinier, (unknown), (unknown), (unknown), Virginie Levrat, (unknown), (unknown), (unknown), (unknown), Alexandra Bedossa, Alexia Letierce, Hugues Morel, D. Debieuvre	1
2	Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World Analysis 2025 ·Clinical Lung Cancer ·(unknown), (unknown), Isabelle Monnet, Charles Ricordel, L. Bigay-Gamé, (unknown), (unknown), (unknown), (unknown), Aurélie Swalduz, (unknown), H. Doubre, (unknown), D. Arpin, Hugues Morel, Rémi Veillon, Bénédicte Clarisse, C. Chouaïd, Laurent Greillier, (unknown)	0
3	COVID-19 among lung cancer patients: Data from a real-life prospective French multicentric study 2024 ·Respiratory Medicine and Research ·O. Molinier, J. Pinsolle, (unknown), Sebastian Schneider, B. Godbert, (unknown), (unknown), C. Dayen, J. Obert, C. Dujon, Patrick Dumont, Sylvie Julien, (unknown), (unknown), Hugues Morel, D. Debieuvre	1
4	Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06–2018 study) 2024 ·Lung Cancer ·(unknown), Pascale Tomasini, Emmanuelle Dantony, (unknown), Charles Ricordel, L. Bigay-Gamé, D. Arpin, Hugues Morel, Rémi Veillon, (unknown), (unknown), P. Fournel, A. Vergnenègre, (unknown), Fabien Subtil, Bénédicte Clarisse, C. Decroisette, C. Chouaïd, Laurent Greillier, Olivier Bylicki	4
5	Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting 2024 ·European Journal of Cancer ·L. Falchero, (unknown), Olivier Molinier, Faraj Al Freijat, (unknown), (unknown), (unknown), L. Belmont, (unknown), (unknown), (unknown), (unknown), (unknown), S. Hominal, Alexia Letierce, Hugues Morel, D. Debieuvre	2
6	Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study) 2023 ·Targeted Oncology ·(unknown), R. Descourt, (unknown), H. Doubre, C. Decroisette, (unknown), G. Le Garff, L. Falchero, (unknown), S. Vieillot, R. Corre, (unknown), (unknown), L. Bigay-Gamé, Hugues Morel, Olivier Molinier, C. Chouaïd, Florian Guisier	2
7	1273P Durvalumab (D) compared to maintenance chemotherapy (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the randomized SAFIR02 LUNG-IMMUNO trial 2020 ·Annals of Oncology ·Fabrice Barlési, Maryam Karimi, Pascale Tomasini, Catherine Daniel, Judith Raimbourg, (unknown), (unknown), Julien Mazières, Olivier Molinier, Clarisse Audigier-Valette, Denis Moro‐Sibilot, Hugues Morel, (unknown), Ivan Bièche, Alicia Tran-Dien, Alexandra Jacquet, Julien Adam, J.C. Soria, Benjamin Besse	0
8	Asthma and Indoor Environment: Usefulness of a Global Allergen Avoidance Method on Asthma Control and Exposure to Molds 2020 ·Mycopathologia ·Jean‐Pierre Gangneux, (unknown), (unknown), Hugues Morel, Séverine Deguen, (unknown), Pierre Le Cann	7
9	Women and COPD: do we need more evidence? 2019 ·European Respiratory Review ·Christophe Gut‐Gobert, A. Cavaillès, A. Dixmier, Stéphanie Guillot, S. Jouneau, Christophe Leroyer, S. Marchand‐Adam, (unknown), J.-C. Meurice, (unknown), Hugues Morel, (unknown), Chantal Rahérison	97
10	Trachéobronchopathie ostéochondroplastique : à propos de 3 cas 2018 ·Revue des Maladies Respiratoires ·Marion Ferreira, Hugues Morel, A. Dixmier, Flavie Arbion, S. Marchand‐Adam	1
11	Prediagnosis weight loss, a stronger factor than BMI, to predict survival in patients with lung cancer 2018 ·Lung Cancer ·Hugues Morel, Bruno Raynard, (unknown), Pierre-Alexandre Hauss, (unknown), G. Oliviéro, (unknown), (unknown), Bernard Asselain, M Grivaux, D. Debieuvre	36
12	Métastases pulmonaires bénignes d’un léiomyome 2018 ·Revue des Maladies Respiratoires ·(unknown), R. Kerdraon, (unknown), (unknown), B. Lemaire, Hugues Morel	0
13	Cancer cachexia (CAX), anorexia and muscle wasting (sarcopenia) assessment in non-small cell lung cancer (NSCLC): an observational study in 531 patients 2017 ·Annals of Oncology ·D. Debieuvre, Hugues Morel, (unknown), Veerle Surmont, David Planchard, Franck Bonnetain, I. Krakowski, (unknown), S. Antoun	1
14	Les comorbidités dans la BPCO 2015 ·Revue de Pneumologie Clinique ·Graziella Brinchault, P. Diot, A. Dixmier, François Goupil, (unknown), Christophe Gut‐Gobert, Christophe Leroyer, S. Marchand‐Adam, (unknown), Hugues Morel, (unknown), A. Cavaillès	7
15	Comorbidities of COPD breakdown → 2013 ·European Respiratory Review ·A. Cavaillès, Graziella Brinchault-Rabin, A. Dixmier, François Goupil, Christophe Gut‐Gobert, S. Marchand‐Adam, J.-C. Meurice, Hugues Morel, (unknown), Christophe Leroyer, P. Diot	360
16	Update on the roles of distal airways in COPD 2011 ·European Respiratory Review ·Pierre‐Régis Burgel, Arnaud Bourdin, Pascal Chanez, F. Chabot, Ari Chaouat, Thierry Chinet, J. de Blic, Philippe Devillier, A. Deschildre, A. Didier, Gilles Garcia, G. Jébrak, François Laurent, Hugues Morel, T. Pérez, Charles Pilette, Nicolás Roche, Isabelle Tillie‐Leblond, Sylvia Verbanck, Daniel Dusser	67
17	Faux anévrisme de l’artère pulmonaire sur récidive de cancer 2008 ·La Presse Médicale ·Arnaud Millet, Hugues Morel, Jean-François Heautot, R. Corre, (unknown)	2
18	Clinical practice guidelines: Medical follow-up of patients with asthma—Adults and adolescents 2005 ·Respiratory Medicine ·Nicolás Roche, Hugues Morel, Philippe Martel, Philippe Godard	28
19	Characterization of Ion and Fluid Transport in Human Bronchioles 2002 ·American Journal of Respiratory Cell and Molecular Biology ·(unknown), Hugues Morel, Jocelyne Hinnrasky, Emmanuel Naline, Édith Puchelle, Thierry Chinet	25
20	Regulation of Electrogenic Anion Secretion in Normal and Cystic Fibrosis Gallbladder Mucosa 1999 ·Hepatology ·Thierry Chinet, Laura Fouassier, (unknown), (unknown), Hugues Morel, Martine Mergey, B. Dousset, R Parc, Annick Paul, Chantal Housset	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact